- In the overall trial population, survival results numerically favored Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan but did not reach statistical significance
- TROPION-Lung01 previously met the dual primary endpoint of progression-free survival in the overall trial population
- Results support applications currently under review by regulatory authorities globally including the U.S. and EU
Reported Monday, Daiichi Sankyo And AstraZeneca's Datopotamab Deruxtecan Show Survival Improvement Versus Chemotherapy In Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer In TROPION-Lung01 Phase 3 Trial
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.